BRPI0406776A - Composição farmacêutica, método de avaliação fisiológica e uso de pelo menos um dentre um inibidor de uma molécula semelhante a resistina (alfa) (relm(alfa)), uma molécula semelhante a resistina ß (relmß), um regulador de expressão de relm(alfa) ou um regulador de expressão de relmß - Google Patents

Composição farmacêutica, método de avaliação fisiológica e uso de pelo menos um dentre um inibidor de uma molécula semelhante a resistina (alfa) (relm(alfa)), uma molécula semelhante a resistina ß (relmß), um regulador de expressão de relm(alfa) ou um regulador de expressão de relmß

Info

Publication number
BRPI0406776A
BRPI0406776A BR0406776-2A BRPI0406776A BRPI0406776A BR PI0406776 A BRPI0406776 A BR PI0406776A BR PI0406776 A BRPI0406776 A BR PI0406776A BR PI0406776 A BRPI0406776 A BR PI0406776A
Authority
BR
Brazil
Prior art keywords
relm
alpha
resistin
regulator
expression
Prior art date
Application number
BR0406776-2A
Other languages
English (en)
Inventor
Marc Elliot Rothenberg
Original Assignee
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Medical Center filed Critical Childrens Hosp Medical Center
Publication of BRPI0406776A publication Critical patent/BRPI0406776A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, MéTODO DE AVALIAçãO FISIOLóGICA E USO DE PELO MENOS UM DENTRE UM INIBIDOR DE UMA MOLéCULA SEMELHANTE A RESISTINA A (RELM<244>), uma molécula semelhante a RESISTINA <225> (RELM<225>), UM REGULADOR DE EXPRESSãO DE RELMA OU UM REGULADOR DE EXPRESSãO DE RELM<225>". Composição e método para alívio de uma resposta alérgica por regulação da expressão de moléculas <244> ou <225> semelhantes a resistina (RELM<244> ou RELM<225>). As RELMs são também reveladas como marcadores para avaliação do estado alérgico do paciente, por exemplo, monitorando a inflamação e/ou a restauração tecidular no pulmão ou nas vias aéreas do paciente asmático. A regulação das RELMs está envolvida na patogênese da inflamação alérgica pulmonar e outras condições induzidas por alérgenos. A constatação do envolvimento da RELM<244> e RELM<225> na asma liga, do ponto de vista de mecanismos, a patogênese da resistência à insulina e obesidade, conhecidas como envolvendo RELMs, à asma.
BR0406776-2A 2003-01-18 2004-01-16 Composição farmacêutica, método de avaliação fisiológica e uso de pelo menos um dentre um inibidor de uma molécula semelhante a resistina (alfa) (relm(alfa)), uma molécula semelhante a resistina ß (relmß), um regulador de expressão de relm(alfa) ou um regulador de expressão de relmß BRPI0406776A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44092203P 2003-01-18 2003-01-18
PCT/US2004/001139 WO2004067026A1 (en) 2003-01-18 2004-01-16 Regulation of allergen induced gene

Publications (1)

Publication Number Publication Date
BRPI0406776A true BRPI0406776A (pt) 2005-12-27

Family

ID=32825146

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406776-2A BRPI0406776A (pt) 2003-01-18 2004-01-16 Composição farmacêutica, método de avaliação fisiológica e uso de pelo menos um dentre um inibidor de uma molécula semelhante a resistina (alfa) (relm(alfa)), uma molécula semelhante a resistina ß (relmß), um regulador de expressão de relm(alfa) ou um regulador de expressão de relmß

Country Status (7)

Country Link
US (1) US20040198686A1 (pt)
EP (1) EP1594525A1 (pt)
JP (1) JP2006517962A (pt)
AU (1) AU2004207476A1 (pt)
BR (1) BRPI0406776A (pt)
CA (1) CA2512808A1 (pt)
WO (1) WO2004067026A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5229866B2 (ja) * 2007-12-12 2013-07-03 国立大学法人広島大学 大腸癌、動脈硬化症、又はメタボリックシンドロームの検出方法
US20090274696A1 (en) * 2008-04-29 2009-11-05 Wyeth Methods for treating inflammation
EP2858679B2 (en) * 2012-06-08 2024-06-05 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
US20230003743A1 (en) * 2020-02-24 2023-01-05 The Children's Medical Center Corporation Methods and compositions for treating or preventing an allergy or anaphylaxis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
HUT76369A (en) * 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
MXPA01006006A (es) * 1998-12-14 2004-08-12 Genetics Inst Cadena receptora de citocina.
AU2001268232A1 (en) * 2000-06-09 2001-12-24 The Trustees Of The University Of Pennsylvania Compositions, methods, and kits relating to resistin-like molecules
JP2002338537A (ja) * 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
AU2003241182A1 (en) * 2002-06-05 2003-12-22 Asahi Kasei Pharma Corporation Stat6 activation gene

Also Published As

Publication number Publication date
JP2006517962A (ja) 2006-08-03
EP1594525A1 (en) 2005-11-16
CA2512808A1 (en) 2004-08-12
WO2004067026A8 (en) 2004-10-21
WO2004067026A1 (en) 2004-08-12
US20040198686A1 (en) 2004-10-07
AU2004207476A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
DE602008021800C5 (de) Antibiotikum zur Behandlung von lokaler Infektion
Chiaradia et al. Gambling on putative biomarkers of osteoarthritis and osteochondrosis by equine synovial fluid proteomics
BR112012014801A2 (pt) &#34;uso combinado de proteínas cry1ca e cry1fa para controle de resistência a insetos&#34;
BR0316231A (pt) Métodos para determinar o estado de sepsia para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo e para isolar um biomarcador, perfil biomarcador r kit
Zeyer et al. Engineered mutations in fibrillin-1 leading to Marfan syndrome act at the protein, cellular and organismal levels
BRPI0710185A8 (pt) anticorpos contra receptor de fator de crescimento i semelhante à insulina e usos dos mesmos
BR0316923A (pt) Polipeptìdeo mitoneet de membranas mitocondriais, seus moduladores e métodos para utilização do mesmo
Mulè et al. Relationships between mild hyperuricaemia and aortic stiffness in untreated hypertensive patients
BRPI0710959B8 (pt) uso de uma proteína anti-secretória ou fragmentos da mesma para a fabricação de uma composição farmacêutica para a prevenção ou tratamento da hipertensão intra-ocular.
BRPI0406776A (pt) Composição farmacêutica, método de avaliação fisiológica e uso de pelo menos um dentre um inibidor de uma molécula semelhante a resistina (alfa) (relm(alfa)), uma molécula semelhante a resistina ß (relmß), um regulador de expressão de relm(alfa) ou um regulador de expressão de relmß
BR112022018111A2 (pt) Anticorpos contra mucina 17 e usos dos mesmos
HRP20050655A2 (en) Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
Jiao et al. The association between the levels of CRP, IL-10, PLA2, Fbg and prognosis in traumatic fracture of lower limb
Bjerrum et al. The carpal tunnel syndrome and amyloidosis. A clinical and histological study
Nakayama et al. Evaluation of glycosaminoglycans levels in normal joint fluid of the knee
Kleef et al. Evaluation of procollagen 1 N propeptide for predicting osteomyelitis and epithelial neutrophil activator-78 for early wound healing in patients with diabetic foot
Nikolic et al. Familial pneumothorax
BR0313667A (pt) Processos para diagnóstico de distúrbios neurológicos relacionados à demência
Sharma et al. Correlation of Serum C-Peptide and Serum uric acid Levels with Glycated Hemoglobin in Patients of Type 2 Diabetes Mellitus
Güvenç et al. Dynamic thiol-disulphide homeostasis in grade 3-4 gonarthrosis
Kaur et al. Assessment of total antioxidant status in acute pancreatitis and prognostic significance
Mirdamadi et al. Congenital Heart Disease with Pulmonary Hypertension; Surgery or Medical Treatment?
ATE412908T1 (de) Insulinpromotor-faktor 1 als target/marker von beta-zellen-störung
Girtovitis et al. Thrombophilia as a Risk Factor for Central Retinal Vein Thrombosis.
MAJID Estimation of Lipid Profile and Kidney Function Test in Hypertensive Patients in Thi Qar Province/Iraq.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]